Hikma launches generic Fusilev injection in the USA

17 August 2016

Jordon-based Hikma Pharmaceuticals (LSE: HIK) revealed that its wholly-owned US affiliate, West-Ward Pharmaceuticals has launched a generic version of Fusilev (levoleutcovorin).

The firm’s levoleucovorin for Injection, 50 mg/vial has been granted a 180-day generic drug exclusivity by the Food and Drug Administration. The injection is therapeutically equivalent to the reference listed drug Fusilev from US drugmaker Spectrum Pharmaceuticals (Nasdaq: SPPI).

Levoleucovorin for Injection is a folate analog indicated for rescue after high dose methotrexate therapy in osteosarcoma and for diminishing the toxicity and counteracting the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists. According to IMS Health, total US combined sales of levoleucovorin were around $116 million for the 12 months ending June 2016.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK